Advertisement

Reactions Weekly

, Volume 1781, Issue 1, pp 174–174 | Cite as

Glecaprevir/pibrentasvir

Various toxicities and drug resistance: 7 case reports
Case report
  • 9 Downloads

Reference

  1. Ikeda H, et al. Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naive noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan. Journal of Viral Hepatitis 26: 1266-1275, No. 11, Nov 2019. Available from: URL: http://doi.org/10.1111/jvh.13170 - JapanCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations